Janagliflozin

DB16209InvestigationalSmall molecule

Janagliflozin is under investigation in clinical trial NCT03851432 (Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin).

Mechanism: Pharmacologically active on Sodium/glucose cotransporter 2
Curator reviewed
Formula / weight: C₂₅H₂₉ClO₆ · 460.95 g/mol (avg)
Code names: XZP-5695

Resolves to

Compound

UNIIWK4RT85HCACAS1800115-22-3ChEMBLCHEMBL4107297

Structure

InChIKeyWDBIPGHUEJEKTC-CGTLGCROSA-NSMILESOC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3C[C@@H]4C[C@@H]4C3)C=C2)=C(Cl)C=C1

Targets

P31639SLC5A2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Janagliflozin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account